GAITHERSBURG, Md., April 18 /PRNewswire-FirstCall/ -- Iomai Corporation today announced that Stanley C. Erck, the company’s president and chief executive officer, is scheduled to present at the UBS Global Specialty Pharmaceutical Conference on Monday April 24, 2006 at 9:00 a.m. EDT. The conference will be held at the Grand Hyatt Hotel, New York City.
To access the live audio webcast or the subsequent archived recording, log on to the Investor Relations section on the Overview page of the Iomai website at www.iomai.com. Please connect to Iomai’s website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.
ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers’ diarrhea. For more information on Iomai, please visit www.iomai.com.
Some matters discussed in this press release constitute “forward-looking statements” that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about TCI ‘s ability to stimulate stronger immune responses, Iomai’s ability to develop new vaccines, and Iomai’s ability to expand the global vaccine market. Applicable risks and uncertainties include, among others, that Iomai may not be able to enroll sufficient numbers of patients in clinical trials to demonstrate the safety and efficacy of its product candidates; that clinical trials may not demonstrate safety and efficacy; that Iomai may be unable to obtain the regulatory approvals necessary to conduct additional clinical trials or to market its product candidates; that development costs may exceed expectations; that Iomai may fail to adequately protect its intellectual property or may be determined to infringe on the intellectual property of others; and the risks identified under the heading “Risk Factors” under Item 1A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 and filed with the Securities and Exchange Commission. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read the Company’s filings for a discussion of these and other risks and uncertainties which are filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.
These statements speak only as of the date of this document, and Iomai undertakes no obligation to update or revise the statements.
Iomai Corporation
CONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel, of Iomai Corporation, +1-301-556-4478, orinvestors@iomai.com; or Daryl Messinger of WeissComm Partners, Inc.,+1-415-999-2361, or daryl@weisscommpartners.com, for Iomai Corporation
Web site: http://www.iomai.com//
